HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

By J. Henter, A. Horne, M. Aricò, R. M. Egeler, A. Filipovich, S. Imashuku, S. Ladisch, K. McClain, D. Webb, J. Winiarski and 1 more. Pediatric Blood & Cancer, 2007

5,036 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/b13be85b7faa5a9a66d685b8d04562abc8bd643b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Miriam Merad
2. B. Rollins

Citations in the corpus

• Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. (2011, neutral): “Mean/median age, mo (range) 24/8 (0-184) 16/2 (0-145) (2*) 23/4 (0-137) 15/4 (0-150) (2*) 51/24 (2-184) (1*)”
• 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis (2016, positive): “the use of the HLH-2004 diagnostic guidelines (24).”
• Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis (2008, background): “Diagnostic criteria include five of eight of the following: fever, splenomegaly, cytopenias, hypertriglyceridemia, and/or hypofibrinogenemia, hyperferritinemia (>500 mg/L), elevated soluble IL-2Ra, decreased NK-cell activity, and hemophagocytosis in bone marrow, CSF or lymph nodes [2].”
• Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. (2017, neutral): “No 52 (17) 26 (19) 26 (15) 41 (20) 11 (11) 31 (15)”
• Serum Ferritin: Past, Present and Future (2010, neutral): “hyperferritinemia (>500 ng/ml), 5) hemophagocytosis, 6) elevated soluble interleukin-2 receptor (CD25), 7) decreased natural killer-cell activity, and 8) splenomegaly(128).”
• Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome (2014, neutral): “In this context, different sets of criteria have been proposed for helping clinicians to diagnose the syndrome (1,8,16–19).”
• Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. (2016, background): “In cases where a molecular diagnosis is lacking, patients can be clinically diagnosedwithHLHupon fulfillment of at least 5 of8diagnostic criteria.(83) First-line treatment of bothprimary and secondary HLH is directed to control the hyperinflammation.”